An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer
Clinical trial NCT06538207 · COMPLETED
Trial details
- NCT number
- NCT06538207
- Sponsor
- Ono Pharmaceutical Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-01-13
- Primary completion
- 2024-10-01
- Enrollment
- 46
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.